Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1986)	12/14/2016 2:05:12 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

Actualy, Geel Belgium facility where Sanofi is investing 300Me is Genzyme facility: Genzyme in GeelGenzyme's state-of-the-art cell culture production facility for therapeutic proteins in Geel is among the largest bio-manufacturing sites in Europe. The facility is designed as a multi-product facility for suspension and continuous mammalian cell culture production. The suspension cell culture capacity includes two 10,000L stirred tank bioreactors, the accompanying seed bioreactors, medium/buffer preparation tanks and purification train. The perfusion cell culture capacity includes two 4000L bioreactors, with seed train and dedicated purification train. A third 4000L bioreactor is currently in validation. Genzyme in Geel has fully equipped quality control laboratories housed within a 4,000 m2 office/laboratory building. Two of Genzyme's main therapies will be manufactured in the Geel facility: A monoclonal antibody for the treatment of B-cell chronic lymphocytic leukemia. The approval for its manufacturing for the EU and the US was received in 2009 and 2010. The treatment is also being evaluated in a number of clinical trials for treatment of other cancers and multiple sclerosis.An enzyme therapy product for the treatment of Pompe disease, a rare but often fatal genetic muscle disorder. The product was approved in 2006 for treatment in Europe and the US. The first regulatory approval for commercial production of this product in Geel was achieved on February 25th, 2009. In the meanwhile further regulatory approval for commercial production of this enzyme was received for other areas: Japan, Canada, US and Brazil. https://www.sanofigenzyme.be/Info/Genzyme-in-Belgium/Geel.aspx Does anyone have ALTERNATIVE Sanofi manufacturing site?